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Results: Five hundred and seventy-five patients were included, 
254 treated with RP and 321 with PB. At RP, 24% had pT3 disease. 
The positive surgical margin rate was 50% and 21% for patients 
with pT3 and pT2 respectively. The median D90 (dose [Gy] that 
covers 90% of the prostate volume) in this study was 159.1 Gy 
(IQR 140.9-176.7 Gy). The D90 was < 130 Gy in 14% of implants. 
Patients who had RP were compared to patients treated with PB: 
RP patients were significantly younger, had less positive pre-
treatment biopsies but a lower rate of Gleason 7 disease. The 
mean PSA was not different. The rate of patients with BCR was 
not different between both groups (p = 0.24) and occurred in 
21.2% after RP and in 20.6% after PB. On univariate and 
multivariate logistic regression analysis, younger age, higher 
percentage of positive biopsies and initial PSA were predictive of 
BCR. Treatment modality was not predictive in either univariate 
(OR 0.96, 95%CI 0.64-1.44 p = 0.58) or multivariate (OR 1.42, 
95%CI 0.88-2.28, p = 0.42) analyses. 
Conclusions: Both RP and PB result in similarly good results at 
four years post treatment with about 20% experiencing BCR, as 
measured with similar PSA-thresholds. Clinical T-Stage, age, 
percentage of positive biopsies and Gleason score are predictive 
of outcome. However, it is possible that study power is 
inadequate and/or follow up is too short to detect a difference 
between both treatments. 
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Purpose: To investigate the effect of D90 on biochemical failure 
in a large consecutive cohort of I125 monotherapy patients. 
Methods and Materials: Between July 1998 and September 2011, 
3436 men with NCCN low- and intermediate-risk prostate cancer 
underwent I125 brachytherapy monotherapy, 3392 (98.6%) of 
whom had post-implant, CT-based dose metrics recorded. Sixty 
percent had intermediate-risk disease and 46% had six months of 
neoadjuvant/concomitant androgen deprivation therapy (ADT). 
The median D90 was 153 Gy (mean 154 Gy, SD 15.9, range 86.5-
223 Gy).The median follow up was 5.48 years (mean 6.12, SD 
3.95, range 0-16.9); 648 men have been followed for at least 10 
years. 
Results: As of September 2015, there have been 222 biochemical 
relapse events (nadir+2 ng/mL threshold) yielding five- and 10-
year K-M biochemical progression free survival (b-PFS) estimates 
of 94.9% (± 1.0%) and 89.9% (± 1.6%) respectively. Intermediate-
risk patients were more than twice as likely to experience 
biochemical failure compared to low-risk (HR 2.13, p < 0.001). In 
a multivariate Cox model, Gleason sum 7 versus ≤6 (HR 2.2, p < 
0.001), pre-treatment PSA (HR 1.14 per unit increase, p < 0.001) 
and clinical T2b-c versus T1c-T2a (HR 1.8, p < 0.001) were each 
strongly associated with increased risk of biochemical failure. 
The use of ADT reduced the risk of biochemical failure (HR 0.51, 
p < 0.001). Post-implant D90 values, age and percent positive 
cores were not statistically associated with biochemical relapse 
in MVA. Although not reaching statistical significance, a small 
dose effect was identified when comparing the annualized risk 
of relapse for years 4-9 post-implant permitting a quantitative 
estimate of the impact of D90 on b-PFS. For intermediate-risk 
patients who did not receive ADT (n = 1019), D90 had no 
measurable impact on the risk of biochemical failure. However, 
for the intermediate-risk patients who did receive ADT (n = 
1085), there was a 1.8% improvement in the ten-year b-PFS for 
each 10 Gy increase in D90. For the low-risk patients, there was 
a 1.4% improvement in the ten-year b-PFS for each 10 Gy 
increase in D90. 
Conclusions: The three conventional prognostic factors (Gleason 
sum, pre-treatment PSA and clinical T-Stage) as well as the use 
of ADT were all strongly associated with biochemical failure in 
MVA. D90 did not reach statistical significance in MVA, but a 
small beneficial effect of increased D90 values was identified. 
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Purpose: To report preliminary outcomes of focal salvage HDR 
brachytherapy for locally recurrent prostate cancer after 
external beam radiotherapy (RT). 
Methods and Materials: All 15 patients entered on a prospective 
study had biopsy proven locally recurrent prostate carcinoma 
visible on MRI, at least 18 months after definitive RT, with > 6 
months PSA doubling time. The GTV was defined using 
multiparametric MRI (T2-weighted, diffusion-weighted, dynamic 
contrast-enhanced). The prostate gland and GTV contours were 
deformably co-registered to T2w images at time of 
brachytherapy after catheter placement using deformable image 
registration. CTV margin expansion (5 mm in all directions) was 
restricted to adjacent OARs and 2 mm beyond the prostate 
boundary where applicable. PTV margins of 2 mm cranio-caudally 
and 1mm elsewhere were then applied. A total dose of 26 Gy in 
two separate implants 7-14 days apart was delivered. No patient 
received androgen deprivation therapy. 
Results: Median follow up was 12 months (range, 3-24). The 
median age at time of enrollment was 72 years (range, 62-77). 
The median pre-brachytherapy PSA was 3.96 ng/ml (range, 1.68 
– 8.39). All patients had a single GTV. Median GTV and PTV 
volumes were 1.45 cc (range, 0.66-6.76) and 6.45 cc (range 3.5-
17.39), respectively. A median of eight catheters (range, 4-12) 
were used. Initial biochemical response after salvage 
brachytherapy was seen in all patients with 14 having > 50% 
reduction from baseline. To date 10 have achieved PSA < 1 
ng/ml, while 10 of 12 patients with > 12 months follow up have 
PSA level < 1 ng/ml. Of two patients who have experienced 
biochemical failure, one had imaging and biopsy evidence of a 
marginal recurrence. Acute toxicity (CTCAE v4.0) was mild. Only 
one patient had Grade 2 toxicity (temporary urinary 
catheterization after his second implant). All acute toxicity has 
resolved in patients who have greater than three months of 
follow up. 
Conclusions: MR-guided focal salvage HDR brachytherapy in 
patients treated with previous RT is associated with minimal 
acute toxicity and initial biochemical response appears 
promising. Further follow up will determine if this approach 
results in acceptable local/biochemical control and late toxicity. 
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Purpose: Exposure of the heart to radiation during radiotherapy 
for breast cancer has been shown to increase the rate of ischemic 
heart disease, with the increase being proportional to the mean 
dose to the heart. Although a significant reduction of heart dose 
has been shown with respiratory-gated irradiation of the left 
breast, there is currently no data on heart dose variation through 
the cardiac cycle. The purpose of this study was to assess dose 
variation to left coronary artery, left ventricle and heart during 
the cardiac cycle using dual source computed tomography 
(DSCT). 4D cardiac motion was used to investigate the potential 
dosimetric advantage of cardiac-gated radiotherapy.  
Methods and Materials: This is a prospective pilot study of 
patients with left-sided breast cancer treated with tangential 
breast irradiation. A planning scan and a contrast-injected 
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cardiac four-dimensional CT (4D-CT) synchronized to the 
electrocardiogram were obtained in treatment position, using a 
prospective sequential acquisition method including the extreme 
phases of systole and diastole. On a MimVista® image 
registration workstation, dose distributions were transferred to 
the cardiac 4D-CT. The left coronary artery, left ventricle and 
heart were contoured on both phases of the cardiac cycle. The 
maximum and minimum doses to the left coronary, left ventricle 
and heart were compared using a bilateral paired Student T test.  
Results: Preliminary data from the first eight patients enrolled 
are presented. Median age was 60 years (56-71) and median 
planned dose to the left breast was 42.56 Gy (42.56-50) in 16 
fractions (16-20). For the left coronary artery, mean dose, V5 
and V20 in systole versus diastole were 6.1 Gy versus 7.9 Gy (p = 
0.02), 37% versus 48% (p = 0.02) and 10% versus 16% (p = 0.04), 
respectively. For the left ventricle, mean dose, V5 and V20 in 
systole versus diastole were 1.3 Gy versus 1.6 Gy (p = 0.005), 6% 
versus 9% (p = 0.03) and 1% versus 2% (p > 0.1), respectively. For 
the whole heart, mean dose, V5 and V20 in systole versus diastole 
were 0.9 Gy versus 1.3 Gy (p = 0.005), 21 cc versus 32 cc (p = 
0.07) and 4 cc versus 5 cc (p > 0.1), respectively. 
Conclusions: Beyond DIBH, systolic irradiation would be 
associated with a further reduction in V5, V20 and mean dose to 
the left coronary artery, as well as a reduction in V5 and mean 
dose to the left ventricle and heart as a whole. The potential 
clinical impact of this reduction as well as the feasibility of 
cardiac gated irradiation are to be further investigated. 
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Purpose: Non-melanoma skin cancers occurring in areas with 
irregular contours like the ear pose challenges in effectively 
delivering a therapeutic radiation dose using electrons. As 
electrons deliver dose at a depth, a tissue equivalent material 
called bolus must be placed on the skin so that therapeutic dose 
is delivered to the tumour. Commercially available bolus 
materials lack the ability to conform to a patient’s specific 
anatomy in areas with irregular contours. Such shortcomings can 
create air cavities between the tumour and bolus, and ultimately 
lead to treatment inaccuracy. A custom bolus can be made from 
wax, but this also has shortcomings. It is labour intensive and 
challenging to create a wax bolus with uniform specified 
thickness and minimal air gaps. As an alternative, we have 
developed a technique of generating soft silicone bolus, which 
conforms to irregular anatomy, using an optical scanner and rigid 
material 3D printer. 
Methods and Materials: Volunteer specific anatomy of the ear 
was acquired using a consumer-grade optical scanner (3D 
Systems, Sense). A three-dimensional model of each volunteer 
was exported to a mesh editing software (Autodesk, MeshMixer 
v2.9) where replica of the ear anatomy was designed. This 
replica was exported as an STL file to software controlling the 
printer (Repetier-Host), converted to gcode (Slic3r) and printed 
on a consumer-Grade 3D printer (MakerGear, M2). This replica 
served as a rigid mould for silicone rubber. The result was a soft 
bolus with one side flat and the other side perfectly fitting the 
ear. 
Results: The soft silicone bolus created by this technique 
perfectly fit the anatomy, was of desired thickness, comfortable 
to put on with no sharp edges. There were no air gaps visible. No 
air bubbles were found using x-ray imaging. Dosimetric studies 
were done on the silicone rubber and it was found acceptable to 
be used as a bolus material. 
Conclusions: Using an optical scanner and 3D printer enables us 
to create a soft, flexible silicone conformal bolus which is cost 
effective. Silicone bolus accurately fits with no air gaps and is 
better for irregular contours than a commercial or wax bolus. It 
is also better than a hard plastic 3D printed bolus for areas where 
a rigid bolus is difficult to use or causes patient discomfort. This 
approach does not require intensive training and enhances the 
patient experience as they can have an optical scan on the day 
of clinical appointment and directly come on the day of 
treatment. It also has potential to save treatment machine time 
because the setup time is anticipated to be reduced as the 
complexity of set up is greatly decreased.  
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Purpose: To determine the rates of urinary intervention for 
patients with low- and low-tier intermediate-risk prostate cancer 
treated with intraoperatively planned low dose rate prostate 
brachytherapy. 
Methods and Materials: From 2003-2012, 723 consecutive 
patients were treated with intraoperatively planned LDR 
prostate brachytherapy without external beam radiotherapy at 
our centre. Dosimetric planning targets were uniform with a goal 
of D90 prostate > 180 Gy, V150 > 74%, V200 > 37%, V140 urethra 
< 24% and V150 urethra < 3%. Patients were followed according 
to a protocol every 6 months for the first three years then 
annually. For each patient, all data were entered into a central 
database prospectively and retrospectively verified by reviewing 
a centralized electronic health record that comprehensively 
captures all interventions performed and visitations to any 
medical centre in the province of Alberta, Canada. Urinary 
interventions included cystoscopy, transurethral resection of the 
prostate, urethral dilatation or catheterization for urinary 
retention or hematuria attributable to brachytherapy. These 
patients were then isolated and compared with the remaining 
control cohort using tests of proportions and multivariate 
analysis as appropriate. 
Results: Median follow up was 7.1 years (range: 2.5 - 12.5). 
Intervention for RTOG Grade 3 toxicity was encountered in 51 
patients (7%). Cystoscopy was done in 31 patients (4.3%) for RT 
related hematuria or obstruction. TURP was performed in 14 
patients (1.9%) with a median time from implant of 20.4 months 
(range, 3-86) and dilatation for RT toxicity in six patients (0.8%) 
with a median time of 29 months (range, 20-85). Median pre-
implant volume was 37.1 cc (20.2 - 53.0) in patients having 
intervention for Grade 3 toxicity and 33.7 cc (13.2 - 66.9) in 
those without [p < 0.05]. Time from biopsy to implant, pre-
treatment AUA symptom score, PSA, clinical stage, use of 
hormones, and urethral dosimetry did not predict for urinary 
intervention in our analysis. 
Conclusions: Urinary intervention rates following 
intraoperatively planned LDR prostate brachytherapy are low 
overall at 7%. The strength of our study is the ability to review 
all hospital records in our health region to completely capture 
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